(RTTNews) - Zealand Pharma A/S (ZLDPF.PK, ZEAL.CO), a biotechnology company focused on metabolic health, announced Friday that the European Commission has granted marketing authorization for Zeydovio (glepaglutide) to treat adults with short bowel syndrome (SBS).
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.